Prevention of neutropenia during chemotherapy by prolonged myelostimulatory preparations

Cover Page
  • Authors: Ptushkin V.V.1,2,3,4, Zhukov N.V.1,5,4, Borisov V.I.6,7, Minenko S.V.8,9, Larina Y.V.1,10
  • Affiliations:
    1. Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia
    2. 1 Samory Mashela St., Moscow, 117198, Russia S.P. Botkin City Clinical Hospital
    3. 5 , 2nd Botkinskiy Pr-d, Moscow, 125284, Russia N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
    4. 1 Ostrovityanova St., Moscow, 117997, Russia
    5. 1 Samory Mashela St., Moscow, 117198, Russia N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
    6. Clinical Oncological Dispensary № 1, Moscow Healthcare Department
    7. 17/1 Baumanskaya St., Moscow, 105005, Russia
    8. S.P. Botkin City Clinical Hospital
    9. 5 , 2nd Botkinskiy Pr-d, Moscow, 125284, Russia
    10. 1 Samory Mashela St., Moscow, 117198, Russia
  • Issue: Vol 10, No 2 (2015)
  • Pages: 37-45
  • Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
  • Published: 04.06.2015
  • URL: https://oncohematology.abvpress.ru/ongm/article/view/143
  • DOI: https://doi.org/10.17650/1818-8346-2015-10-2-37-45
  • ID: 143

Cite item

Full Text

Abstract

Neutropenia and associated infection, resulting in hospitalization and use of antibiotics, has a negative effect on chemotherapy. The need to reduce the dose of cytotoxic drugs during neutropenia leads to lower survival rates in patients with hematological malignancies and solid tumors. Since 1990s myelocytokines – proteins that accelerate neutrophil recovery after cytostatic chemotherapy and reduce the risk of infection – is widely used in the clinical practice. The use of these drugs can support the planned dose intensity of chemotherapy and improves the treatment efficacy. The disadvantages of these drugs include the need for their daily parenteral administration for 7–10 days. The development of long-acting forms (pegfilgrastim and lipegfilgrastim) has solved this problem. Self-regulating clearance of prolonged forms allowed to use them only once on a chemotherapy course. Results of pegfilgrastim administration in 25 patients with hematological malignancies (8 patients) and solid tumors (17 patients) included in our analysis. Prolonged preparation showed high efficacy in secondary prophylaxis of neutropenia and infection decreasing the risk by 82 %. The single administration of pegfilgrastim allowed safe dose intensity chemotherapy with shorter intervals between courses (AC-14) in 8 patients with breast cancer. Tolerability was good; cases of hyperleukocytosis have notbeen reported. Recently in Europe and the Russian Federation a new drug from prolonged myelocytokine group – lipegfilgrastim – has been 
registered. The results of two controlled trials in patients with breast cancer (n = 410) receiving doxorubicin/docetaxel showed high efficacy of the drug as the pegfilgrastim with comparable tolerability.

About the authors

V. V. Ptushkin

Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, Russia

S.P. Botkin City Clinical Hospital; 5 , 2nd Botkinskiy Pr-d, Moscow, 125284, Russia

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; 1 Ostrovityanova St., Moscow, 117997, Russia

Author for correspondence.
Email: vadimvadim@inbox.ru
Russian Federation

N. V. Zhukov

Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, Russia

N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; 1 Ostrovityanova St., Moscow, 117997, Russia

Russian Federation

V. I. Borisov

Clinical Oncological Dispensary № 1, Moscow Healthcare Department; 17/1 Baumanskaya St., Moscow, 105005, Russia

Russian Federation

S. V. Minenko

S.P. Botkin City Clinical Hospital; 5 , 2nd Botkinskiy Pr-d, Moscow, 125284, Russia

Russian Federation

Yu. V. Larina

Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, Russia

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.